U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688070) titled 'Verapamil Effect in Cystic Fibrosis-related Dysglycemia' on June 30.
Brief Summary: We are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the safety and efficacy of verapamil on beta cell function and dysglycemia.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Cystic Fibrosis Related Diabetes
Cystic Fibrosis (CF)
Abnormal Glucose Tolerance
Intervention:
DRUG: Verapamil Hydrochloride
Verapamil extended release (ER) will be initiated at a dose of 120mg daily and u...